Avita Medical Ltd. CEO William Dolphin, Ph.D. Interviewed by Stock News Now

Avita Medical Ltd. CEO William Dolphin, Ph.D. Interviewed by Stock News Now 
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) --
02/14/13 --   William Dolphin, Ph.D., the CEO of regenerative
medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), was
interviewed by SNNLive last week. Dr. Dolphin provides an update on
Avita's flagship product, ReCell(R) Spray-On Skin(R). Based on
Avita's proprietary technology, ReCell is designed to provide a
rapid, safe and effective point of care treatment for regrowing skin
tissue that has been damaged due to trauma, disease, or senescence. 
Watch the video here: 
http://www.youtube.com/watch?v=wJ5GMxfhuXQ&list=UUZLIt722xmGPXAqTafNnM3w&index=6 
Dr. Dolphin emphasizes that ReCell(R) addresses a wide range of
markets including "acute wounds, burns, chronic wounds, diabetic foot
ulcers, venous leg ulcers, plastic reconstructive, acne scarring, and
vitiligo." The interview showcases a comprehensive overview of Avita
Medical, touching on company history, products overview, current and
pending approvals, and market size potential. Dr. Dolphin also
discusses Avita's strategy of building the foundation for growth via
clinical studies, research and development, and reimbursement. 
For more information, please visit Avita's website at
http://www.avitamedical.com. 
ABOUT AVITA MEDICAL LTD.
 Avita Medical
(http://www.avitamedical.com/) develops and distributes regenerative
products for the treatment of a broad range of wounds, scars and skin
defects. Avita's patented and proprietary tissue-culture, collection
and application technology provides innovative treatment solutions
derived from a patient's own skin. The company's lead product,
ReCell(R) Spray-On Skin(TM), is used in a wide variety of burns,
chronic wounds, plastic, reconstructive and cosmetic procedures.
ReCell is patented, CE-marked for Europe, TGA-registered in
Australia, and SFDA-cleared in China. ReCell is not available for
sale in the United States; in the US ReCell is an investigational
device limited by federal law to investigational use. An FDA trial on
the safety and efficacy of ReCell is in process.  
Contact:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer 
Phone:+1 838-352-9400
Email: ssung@avitamedical.com 
Investor Relations:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone:+1 646-863-6893
Email: jramson@proactivecapitalgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.